
About Brawn Biotech Limited
Data last updated:
Brawn Biotech Limited is a public limited company based in Delhi, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 07 November 1985 and has been in existence for over 41 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN L74899DL1985PLC022468. Its GSTIN is 07AAACB2655D1Z4 (Delhi). The company holds 2 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 530207.
The company has an authorised share capital of ₹4.5 Cr and a paid-up capital of ₹3 Cr. It was formerly known as Brawn Pharmaceuticals Limited and Brawn Pharmaceuticals Private Limited. It is led by directors including Brij Raj Gupta and Mayank Jain.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at First Floor C – 64 Lagpat Nagar – 1, Delhi, India – 110024.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹16.98 Cr, a growth of 26.2% compared to the previous year. For the same year it recorded a net profit of ₹96 Lakh (net margin 5.7%) and EBITDA of -₹31 Lakh (EBITDA margin -1.8%). The net worth stands at ₹4.34 Cr (up 29.2% YoY). Total assets are valued at ₹5.69 Cr (down 49% YoY).
The company is associated with 2 brands: Brawnpharma and Brawn Biotech. As per MCA filings, the company has satisfied charges of ₹30.28 Lakh on record. Court records list 30 cases involving the company, including 25 filed by the company and 5 filed against it; 5 cases are pending. The company has 5 deals on record (5 market trades); the latest was in December 2024. Its 4 peer companies in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading) are compared by revenue, 1 larger and 3 smaller; the largest is Swaradhya Healthcare Private Limited with revenue of ₹13.65 Cr. The company has 10 MSME Form 1 returns on record between 2019 and 2024, listing 31 overdue payments to 9 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website brawnbiotech.com.
Company details
Name history
Brawn Biotech has undergone 4 name changes throughout its history. The current legal name is Brawn Biotech Limited.
| Company Name | Status |
|---|---|
| Brawn Biotech Limited | Current |
| Brawn Pharmaceuticals Limited | Previous |
| Brawn Pharmaceuticals Private Limited | Previous |
| Brawn Pharmaceuticals Ltd | Previous |
| Brawn Pharmaceuticals P Ltd | Previous |
Contact details
Brawn Biotech Limited's registered office is in Delhi, Delhi. Its website is brawnbiotech.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressFirst Floor C – 64 Lagpat Nagar – 1, Delhi, India – 110024
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Brawn Biotech Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Brawn Biotech operates two associated brands: Brawnpharma and Brawn Biotech. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical formulations are distributed across major healthcare segments. | brawnbiotech.com | |
| Pharmaceutical products are developed and distributed by Brawnpharma. | brawnpharma.com |
Business activity
The main business activity of Brawn Biotech is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Brawn Biotech Limited, buy the company report.
Financials of Brawn Biotech Limited
FY 2025-26 filings availableBrawn Biotech Limited reported revenue of ₹16.98 Cr (up 26.2% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 16.98 | 13.46 | 16.49 | 22.23 | 8.62 | 34.98 | 49.62 |
| Revenue growth | +26.2% | -18.4% | -25.8% | +157.9% | -75.4% | -29.5% | - |
| EBITDA | (0.31) | (1.78) | (1.47) | (0.29) | (2.00) | (0.59) | 0.74 |
| EBITDA margin | -1.8% | -13.2% | -8.9% | -1.3% | -23.2% | -1.7% | +1.5% |
| Profit before tax | 0.02 | (1.80) | (1.54) | (0.40) | (2.11) | (0.35) | 0.83 |
| Net profit | 0.96 | (1.74) | (1.23) | (0.85) | (1.64) | (0.55) | 0.60 |
| Net profit margin | +5.7% | -12.9% | -7.5% | -3.8% | -19.0% | -1.6% | +1.2% |
| EPS (₹) | 3.14 | (5.80) | (4.16) | (2.89) | (5.48) | (1.84) | 1.97 |
| Balance sheet | |||||||
| Total assets | 5.69 | 11.16 | 8.08 | 6.48 | 7.46 | 8.97 | 9.37 |
| Net worth | 4.34 | 3.36 | 5.06 | 6.31 | 7.22 | 8.79 | 9.26 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 0.28 | 0.20 | 0.40 | 0.44 | 0.22 | 0.40 | 0.40 |
| Net working capital | 1.95 | 8.18 | 6.63 | 5.35 | 5.86 | 7.83 | 8.29 |
| Cash flow | |||||||
| Cash from operations | 0.77 | 0.05 | (0.03) | 0.32 | 0.19 | 0.03 | (0.08) |
| Cash from investing | (0.03) | (0.24) | (0.01) | (0.10) | (0.30) | 0.00 | (0.02) |
| Cash from financing | 0.00 | 0.00 | 0.00 | (0.01) | (0.06) | (0.04) | (0.05) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.62 | 6.08 | 1.98 | 4.31 | 4.89 | 5.80 | 2.26 | 3.84 |
| Revenue growth (YoY) | +14.9% | +4.8% | -12.4% | +12.2% | +48.2% | +42.9% | - | - |
| Other income | 0.14 | 0.14 | 0.18 | 0.09 | 0.09 | 0.09 | 0.09 | 0.00 |
| Total expenses | 5.70 | 6.03 | 2.48 | 4.32 | 4.88 | 5.62 | 2.81 | 4.25 |
| EBITDA | (0.08) | 0.05 | (0.50) | (0.01) | 0.01 | 0.18 | (0.55) | (0.41) |
| EBITDA margin | -1.4% | +0.8% | -25.3% | -0.2% | +0.2% | +3.1% | -24.3% | -10.7% |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.03 | 0.16 | (0.35) | 0.05 | 0.07 | 0.24 | (0.49) | (0.44) |
| Tax | 0.00 | 0.00 | (0.94) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.62 | 6.08 | 1.98 | 4.31 | 4.89 | 5.80 | 2.26 | 3.84 |
| Revenue growth (YoY) | +14.9% | +4.8% | -12.4% | +12.2% | +48.2% | +42.9% | - | - |
| Other income | 0.14 | 0.14 | 0.18 | 0.09 | 0.09 | 0.09 | 0.09 | 0.00 |
| Total expenses | 5.70 | 6.03 | 2.48 | 4.32 | 4.88 | 5.62 | 2.81 | 4.25 |
| EBITDA | (0.08) | 0.05 | (0.50) | (0.01) | 0.01 | 0.18 | (0.55) | (0.41) |
| EBITDA margin | -1.4% | +0.8% | -25.3% | -0.2% | +0.2% | +3.1% | -24.3% | -10.7% |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.03 | 0.16 | (0.35) | 0.05 | 0.07 | 0.24 | (0.49) | (0.44) |
| Tax | 0.00 | 0.00 | (0.94) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 16.98 | 13.46 | 16.49 | 22.23 | 8.62 | 34.98 | 49.62 |
| Revenue growth | +26.2% | -18.4% | -25.8% | +157.9% | -75.4% | -29.5% | - |
| Other income | 0.45 | 0.09 | 0.09 | 0.01 | 0.00 | 0.31 | 0.17 |
| Total expenses | 17.29 | 15.24 | 17.96 | 22.52 | 10.62 | 35.57 | 48.88 |
| Employee cost | 0.68 | 1.13 | 1.40 | 1.40 | 1.80 | 2.36 | 3.08 |
| EBITDA | (0.31) | (1.78) | (1.47) | (0.29) | (2.00) | (0.59) | 0.74 |
| EBITDA margin | -1.8% | -13.2% | -8.9% | -1.3% | -23.2% | -1.7% | +1.5% |
| Depreciation | 0.12 | 0.11 | 0.10 | 0.11 | 0.05 | 0.03 | 0.03 |
| Interest | 0.00 | 0.00 | 0.06 | 0.01 | 0.06 | 0.04 | 0.05 |
| Profit before tax | 0.02 | (1.80) | (1.54) | (0.40) | (2.11) | (0.35) | 0.83 |
| Tax | (0.94) | (0.06) | (0.30) | 0.45 | (0.47) | 0.20 | 0.23 |
| Net profit | 0.96 | (1.74) | (1.23) | (0.85) | (1.64) | (0.55) | 0.60 |
| Net profit margin | +5.7% | -12.9% | -7.5% | -3.8% | -19.0% | -1.6% | +1.2% |
| EPS (₹) | 3.14 | (5.80) | (4.16) | (2.89) | (5.48) | (1.84) | 1.97 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| Reserves & surplus | 1.34 | 0.36 | 2.06 | 3.31 | 4.22 | 5.79 | 6.26 |
| Shareholders' funds (net worth) | 4.34 | 3.36 | 5.06 | 6.31 | 7.22 | 8.79 | 9.26 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total liabilities | 5.69 | 11.16 | 8.08 | 6.48 | 7.46 | 8.97 | 9.37 |
| Assets | |||||||
| Gross block | 1.05 | 1.02 | 0.78 | 0.77 | 0.67 | 0.38 | 0.38 |
| Net block | 0.36 | 0.46 | 0.33 | 0.37 | 0.38 | 0.14 | 0.18 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 10.06 | 10.47 | 6.02 | 4.79 | 4.72 | 0.26 | 0.39 |
| Sundry debtors | 3.55 | 3.41 | 3.88 | 5.32 | 2.81 | 9.28 | 15.00 |
| Cash & bank balances | 0.28 | 0.20 | 0.40 | 0.44 | 0.22 | 0.40 | 0.40 |
| Loans & advances | 3.23 | 3.43 | 2.84 | 2.85 | 4.43 | 2.79 | 3.42 |
| Total current assets | 17.12 | 17.51 | 13.14 | 13.40 | 12.18 | 12.73 | 19.21 |
| Total current liabilities | 15.17 | 9.33 | 6.51 | 8.05 | 6.32 | 4.90 | 10.92 |
| Net working capital | 1.95 | 8.18 | 6.63 | 5.35 | 5.86 | 7.83 | 8.29 |
| Total assets | 5.69 | 11.16 | 8.08 | 6.48 | 7.46 | 8.97 | 9.37 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.20 | 0.00 | 0.44 | 0.22 | 0.40 | 0.40 | 0.54 |
| Net cash from operating activities | 0.77 | 0.05 | (0.03) | 0.32 | 0.19 | 0.03 | (0.08) |
| Net cash from investing activities | (0.03) | (0.24) | (0.01) | (0.10) | (0.30) | 0.00 | (0.02) |
| Net cash from financing activities | 0.00 | 0.00 | 0.00 | (0.01) | (0.06) | (0.04) | (0.05) |
| Net change in cash | 0.74 | (0.20) | (0.04) | 0.21 | (0.17) | 0.00 | (0.14) |
| Closing cash | 0.28 | 0.20 | 0.40 | 0.44 | 0.22 | 0.40 | 0.40 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +26.2% | -18.4% | -25.8% | +157.9% | -75.4% | -29.5% | - |
| EBITDA growth | +82.6% | -21.1% | -406.9% | +85.5% | -239.0% | -179.7% | - |
| PBT growth | +9998.0% | -16.9% | -285.0% | +81.0% | -502.9% | - | -54.4% |
| Net income growth | +155.2% | -41.5% | -44.7% | +48.2% | -198.2% | -191.7% | - |
| Revenue CAGR (3Y) | -8.6% | +16.0% | -22.2% | -23.5% | -49.1% | -14.4% | -6.4% |
| EBITDA CAGR (3Y) | +2.3% | -3.8% | +35.6% | - | - | - | -15.6% |
| Profitability & leverage | |||||||
| Net income margin | +5.7% | -12.9% | -7.5% | -3.8% | -19.0% | -1.6% | +1.2% |
| Return on capital employed | 0.0% | 0.0% | -20.5% | -5.7% | -25.0% | -3.5% | +9.6% |
| Return on net worth | +22.2% | 0.0% | -22.0% | -12.9% | -20.5% | -6.1% | +6.6% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | -3.82 | -2.50 | -2.93 | -6.45 | 7.04 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 16.41 | 14.96 | 21.28 | 30.88 | 16.42 | 92.05 | 132.32 |
| Inventory turnover | 1.65 | 1.63 | 3.05 | 4.68 | 3.46 | 107.63 | 135.95 |
| Debtors turnover | 4.88 | 3.69 | 3.58 | 5.47 | 1.43 | 2.88 | 3.15 |
| EPS (₹) | 3.14 | (5.80) | (4.16) | (2.89) | (5.48) | (1.84) | 1.97 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 14.46 | 11.21 | 16.88 | 21.03 | 24.07 | 29.31 | 30.87 |
To see the full year-wise statements and ratios of Brawn Biotech Limited, buy the company report.
Board of directors of Brawn Biotech Limited
Brawn Biotech has 3 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Brij Raj Gupta | Director | 07 Nov 1985 | 41 Years 0 Months | Current |
| Mayank Jain | Director | 27 Aug 2024 | 2 Years 2 Months | Current |
| Pooja Jha Also directs: Brawn Laboratories Limited | Director | 27 Aug 2024 | 2 Years 2 Months | Current |
Peer comparison
Brawn Biotech Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Brawn Biotech Limitedthis company | ₹16.98 Cr (FY 2026) | ₹96 Lakh | 5.7% | 26.2% | Delhi, India | |
| Swaradhya Healthcare Private Limited | ₹13.65 Cr (FY 2025) | -8.0% | Lajpat Nagar, Uttar Pradesh, India | |||
| Sri Devi Distributors Private Limited | ₹13.52 Cr (FY 2024) | 30.0% | Chennai, Tamil Nadu, India | |||
| Ryvis Pharma Private Limited | ₹13.51 Cr (FY 2024) | 44.0% | New Delhi, Delhi, India | |||
| Vivan Acidchem Private Limited | ₹13.5 Cr (FY 2022) | 6.0% | Indore, Madhya Pradesh, India |
To see the full peer comparison of Brawn Biotech Limited, buy the company report.
Auditor
Brawn Biotech Limited is audited by RAJIV UDAI AND ASSOCIATES for the financial year 2022.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| RAJIV UDAI AND ASSOCIATES | FY 2022 | 018764N |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 52.90%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.40% and retail and other public shareholders hold 46.70%.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 52.90% | 53.40% | 53.70% | 53.70% |
| Public | 47.10% | 46.60% | 46.30% | 46.30% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 21 Apr 2015 | 10568782 | Punjab National Bank | ₹6.74 Lakh | Satisfied | |
| 21 Apr 2015 | 10569321 | Punjab National Bank | ₹6.74 Lakh | Satisfied | |
| 09 Apr 2014 | 10501704 | Punjab National Bank | ₹14.6 Lakh | Satisfied | |
| 01 Sep 2011 | 10313800 | Punjab National Bank | ₹2.2 Lakh | Satisfied |
To see the full charge records of Brawn Biotech Limited, buy the company report.
Total charge records: 4 View all charges
Deals & funding
Brawn Biotech Limited has 5 deals on record (5 market trades); the latest was in December 2024.
Deals on record (5 of 5)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2024 | Market trade | ₹4 Lakh | Buyer: an individual Seller: an individual |
| Jan 2016 | Market trade | ₹10.7 Lakh | Seller: an individual |
| Jun 2009 | Market trade | ₹4.3 Lakh | Seller: an individual |
| May 2009 | Market trade | ₹5.3 Lakh | Seller: an individual |
| Sep 2005 | Market trade | ₹10.9 Lakh | Buyer: an individual |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Brawn Biotech Limited has 30 court cases on record: 25 filed by Brawn Biotech, 5 filed against it. 5 cases are pending and 25 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 25 | 4 | 4 |
| High courts | 3 | 1 | 1 |
| Supreme Court | 2 | 0 | 0 |
Cases on record (5 of 30)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Delhi | Commercial suit | Filed by the company against Brawn Healthcare India P. Ltd. & Anr. | Pending |
| District court, Central, Delhi | Court case (RCT ARCT) | Filed by the company against The Delhi Stock Exchange Ltd. | Disposed |
| District court, Narnaul, Haryana | Court case (TRAFFIC) | Filed against the company by State of Haryana | Pending |
| District court, Gautam Buddha Nagar, Uttar Pradesh | Criminal case | Filed by the company against an individual | Pending |
| District court, New Delhi, Delhi | Criminal case | Filed by the company against an individual | Pending |
To see the full case history of Brawn Biotech Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Brawn Biotech Limited has 10 MSME Form 1 returns on record between 2019 and 2024, listing 31 overdue payments to 9 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 9)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Stalwart Facilities | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| Triage Meditech Private Limited |
To see the full MSME payment records of Brawn Biotech Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Brawn Biotech has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAACB2655D1Z4 | Delhi | Active | 25 Sep 2017 |
| 06AAACB2655D1Z6 | Haryana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Brawn Biotech Limited, buy the company report.
Recent activity
Brawn Biotech Limited has 31 board changes on record since 1985: 17 appointments and 14 cessations. The latest: Brij Bala Gupta ceased to be Director on 25 Nov 2025.
30 earlier events are in the company report.
Frequently asked questions
Brawn Biotech is an active public limited company based in Delhi, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 07 November 1985 (41+ years old) and is registered under CIN L74899DL1985PLC022468. Listed on BSE: 530207.
Brawn Biotech reported revenue of ₹16.98 Cr for FY 2025-26 (up 26.2% YoY) based on standalone financials.
Brawn Biotech has 3 current directors:
- Brij Raj Gupta - Director
- Mayank Jain - Director
- Pooja Jha - Director
The latest financial statements of Brawn Biotech on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Brawn Biotech is 07AAACB2655D1Z4, registered in Delhi. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 06AAACB2655D1Z6 (Haryana).
The CIN (Corporate Identification Number) of Brawn Biotech is L74899DL1985PLC022468. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Brawn Biotech is a listed company as per MCA records. Its shares are listed on BSE (code: 530207).
Brawn Biotech has 30 court cases on record: 25 filed by the company and 5 filed against it. 5 are pending. Most are in the district courts.
Brawn Biotech was incorporated on 07 November 1985, making it 41+ years old. It is registered with the Registrar of Companies, Delhi.
Brawn Biotech has 5 deals on record (5 market trades); the latest was in December 2024.
The peers of Brawn Biotech by revenue are Swaradhya Healthcare Private Limited, Sri Devi Distributors Private Limited, Ryvis Pharma Private Limited, Vivan Acidchem Private Limited, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Brij Bala Gupta ceased to be Director on 25 Nov 2025. Kanta Takkar ceased to be Director on 27 Aug 2024. Mayank Jain was appointed as Director on 27 Aug 2024. Brawn Biotech has 31 board changes on record in total.

